GSK Deepens Wager On Adaptimmune's Affinity-Enhanced TCR Program
This article was originally published in The Pink Sheet Daily
Executive Summary
With promising data in a sarcoma of the joints, the biotech and its pharma partner plan to move into pivotal studies this year and also try out their lead candidate in combination therapy with checkpoint inhibitors.